Stock Scorecard



Stock Summary for Immunocore Holdings plc (IMCR) - $28.56 as of 1/14/2025 9:10:41 PM EST

Total Score

10 out of 30

Safety Score

36 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for IMCR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for IMCR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for IMCR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for IMCR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for IMCR (36 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for IMCR

Exelixis Provides Preliminary 2024 Results and Outlook for 2025 1/13/2025 3:35:00 PM
Wall Street Analysts Believe Immunocore ( IMCR ) Could Rally 113.13%: Here's is How to Trade 1/13/2025 2:55:00 PM
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib 1/10/2025 6:42:00 PM
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference 1/10/2025 12:00:00 PM
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints 1/7/2025 7:14:00 PM
New Strong Buy Stocks for January 7th 1/7/2025 12:09:00 PM
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference 1/6/2025 12:00:00 PM
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development - Immunocore Hldgs ( NASDAQ:IMCR ) 1/2/2025 12:00:00 PM
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development 1/2/2025 12:00:00 PM
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why 12/27/2024 3:10:00 PM

Financial Details for IMCR

Company Overview

Ticker IMCR
Company Name Immunocore Holdings plc
Country USA
Description Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date 2/26/2025

Stock Price History

Last Day Price 28.56
Price 4 Years Ago 34.24
Last Day Price Updated 1/14/2025 9:10:41 PM EST
Last Day Volume 332,654
Average Daily Volume 291,677
52-Week High 76.98
52-Week Low 27.69
Last Price to 52 Week Low 3.14%

Valuation Measures

Trailing PE N/A
Industry PE 126.08
Sector PE 39.87
5-Year Average PE -13.92
Free Cash Flow Ratio 1.59
Industry Free Cash Flow Ratio 17.04
Sector Free Cash Flow Ratio 26.80
Current Ratio Most Recent Quarter 3.78
Total Cash Per Share 18.01
Book Value Per Share Most Recent Quarter 7.55
Price to Book Ratio 4.03
Industry Price to Book Ratio 5.65
Sector Price to Book Ratio 20.45
Price to Sales Ratio Twelve Trailing Months 5.13
Industry Price to Sales Ratio Twelve Trailing Months 14.30
Sector Price to Sales Ratio Twelve Trailing Months 24.44
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 50,033,000
Market Capitalization 1,428,942,480
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 822.00%
Annual Earnings Growth -5.22%
Reported EPS 12 Trailing Months -0.95
Reported EPS Past Year -0.55
Reported EPS Prior Year -63.59
Net Income Twelve Trailing Months -47,046,000
Net Income Past Year -55,287,000
Net Income Prior Year -52,543,000
Quarterly Revenue Growth YOY 23.70%
5-Year Revenue Growth 43.05%
Operating Margin Twelve Trailing Months -10.60%

Balance Sheet

Total Cash Most Recent Quarter 901,282,000
Total Cash Past Year 442,626,000
Total Cash Prior Year 332,539,000
Net Cash Position Most Recent Quarter 462,587,000
Net Cash Position Past Year 294,615,000
Long Term Debt Past Year 148,011,000
Long Term Debt Prior Year 39,500,000
Total Debt Most Recent Quarter 438,695,000
Equity to Debt Ratio Past Year 0.71
Equity to Debt Ratio Most Recent Quarter 0.46
Total Stockholder Equity Past Year 368,843,000
Total Stockholder Equity Prior Year 338,903,000
Total Stockholder Equity Most Recent Quarter 377,827,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 51,431,000
Free Cash Flow Per Share Twelve Trailing Months 1.03
Free Cash Flow Past Year -2,485,000
Free Cash Flow Prior Year -51,406,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.31
MACD Signal -0.54
20-Day Bollinger Lower Band 28.11
20-Day Bollinger Middle Band 31.61
20-Day Bollinger Upper Band 35.11
Beta 0.72
RSI 50.04
50-Day SMA 44.03
150-Day SMA 49.03
200-Day SMA 45.39

System

Modified 1/14/2025 3:29:39 AM EST